Clinical trials: Physical Abuse
Opioid-related Disorders, Opioid Addiction
ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning
Study to evaluate the impact of the ER/LA opioid REMS program on the incidence of Emergency Department visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.
- Conditions
- Opioid-related Disorders, Opioid Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02866266
- Testing
- Retrospective database review
- Volunteers
- 183,452 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
E-cigarette Use, Cigarette Smoking
BIDI Stick ENDS Abuse Liability and Puffing Topography Assessment
This study assessed the abuse liability (measured by assessing how much nicotine enters the body when the BIDI Stick is used, and how this makes users feel) and puffing topography (puff characteristics like volume and duration)…
- Trial name
- NCT05072925
- Testing
- Tobacco products
- Where
- Poland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BIDI Vapor
Pain
Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza
The purpose of this study is to provide information in a broad, "real world" population of chronic pain patients assessing both pain control with AVINZA as well as the potential risk for misuse and abuse.
- Trial name
- ACCESS 2008 (NCT00640042)
- Testing
- morphine sulfate extended release capsules
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 1,570 people
- Sponsor
- Pfizer
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Abuse Physical Battered Woman Syndrome
Impact of Women's Empowerment Program for Abused Pregnant Women
Although domestic violence is recognized as major threat in pregnancy, there is no intervention has been developed or test to support women in India.
- Trial name
- NCT01933555
- Testing
- Empowerment Program
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Macmillan Research Group UK
Baseline Epidemiologic Assessment
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nationally-projected quarterly…
- Trial name
- BEAD-MB (NCT04033094)
- Testing
- MorphaBond ER, Comparator Drug
- Where
- United States
- Volunteers
- 17,566 people
- Sponsor
- Daiichi Sankyo
Human Abuse Potential
Assessment of Abuse Potential of Cebranopadol in Humans
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
- Trial name
- NCT05256108
- Testing
- Oxycodone 40 mg, Tramadol 600 mg, Cebranopadol 600 µg
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Depressive Disorder, Major
PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011
Bupropion hydrochloride was first approved on 30 December 1985 in United States for depression and is currently approved in 80 countries.
- Trial name
- NCT02039960
- Testing
- Bupropion
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Narcotic Abuse, Opioid-related Disorders
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine sulfate CR tablets and placebo in healthy male…
- Conditions
- Narcotic Abuse, Opioid-related Disorders, Analgesia, Chronic Pain
- Trial name
- NCT01595867
- Testing
- EMBEDA - morphine sulfate/ naltrexone hydrochloride, morphine sulfate CR crushed.
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Human Abuse Potential
Assessment of Abuse Potential of Rapastinel in Humans
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative…
- Trial name
- NCT03799900
- Testing
- Rapastinel, Ketamine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc